We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$5.58B
AUM Growth
+$568M
Cap. Flow
+$189M
Cap. Flow %
3.39%
Top 10 Hldgs %
17.58%
Holding
1,590
New
158
Increased
732
Reduced
501
Closed
88

Sector Composition

Rank Sector Weight
1 Technology 17.89%
2 Financials 10.71%
3 Healthcare 10.59%
4 Consumer Discretionary 9.99%
5 Industrials 8.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AZEK
1101
DELISTED
The AZEK Co
AZEK
$427K 0.01%
10,051
+1,251
+14% +$56.1K
PCI
1102
DELISTED
PIMCO Dynamic Credit and Mortgage Income Fund
PCI
$427K 0.01%
19,070
-373
-2% -$8.42K
HLT icon
1103
Hilton Worldwide
HLT
$72.1B
$422K 0.01%
3,495
+42
+1% +$5.25K
PAC icon
1104
Grupo Aeroportuario del Pacifico
PAC
$12.9B
$421K 0.01%
+3,935
New +$428K
SABR icon
1105
Sabre
SABR
$731M
$421K 0.01%
33,770
+1,640
+5% +$23.1K
SONO icon
1106
Sonos
SONO
$1.73B
$420K 0.01%
11,935
-2,717
-19% -$102K
VRTX icon
1107
Vertex Pharmaceuticals
VRTX
$121B
$420K 0.01%
2,081
-2,954
-59% -$618K
ARKQ icon
1108
ARK Autonomous Technology & Robotics ETF
ARKQ
$1.9B
$419K 0.01%
4,860
+255
+6% +$21K
FNDF icon
1109
Schwab Fundamental International Large Company Index ETF
FNDF
$24.9B
$418K 0.01%
12,574
+2,561
+26% +$86.1K
NHI icon
1110
National Health Investors
NHI
$3.72B
$416K 0.01%
6,202
+611
+11% +$42.6K
KBE icon
1111
State Street SPDR S&P Bank ETF
KBE
$1.64B
$413K 0.01%
8,042
+1,532
+24% +$81.7K
SUNS
1112
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
$404K 0.01%
26,590
+707
+3% +$11K
HZO icon
1113
MarineMax
HZO
$759M
$400K 0.01%
+8,214
New +$428K
IHE icon
1114
iShares US Pharmaceuticals ETF
IHE
$1.46B
$400K 0.01%
6,453
ETR icon
1115
Entergy
ETR
$50.2B
$399K 0.01%
8,004
+2,620
+49% +$138K
IOVA icon
1116
Iovance Biotherapeutics
IOVA
$1.82B
$399K 0.01%
15,339
-1,348
-8% -$35K
VAW icon
1117
Vanguard Materials ETF
VAW
$2.95B
$399K 0.01%
+2,207
New +$408K
SDHY
1118
PGIM Short Duration High Yield Opportunities Fund
SDHY
$398M
$398K 0.01%
20,000
VUZI icon
1119
Vuzix
VUZI
$194M
$398K 0.01%
+21,692
New +$438K
ALNY icon
1120
Alnylam Pharmaceuticals
ALNY
$27.5B
$397K 0.01%
2,339
CLB icon
1121
Core Laboratories
CLB
$490M
$397K 0.01%
10,197
-20
-0.2% -$717
ALXN
1122
DELISTED
Alexion Pharmaceuticals
ALXN
$397K 0.01%
2,163
+57
+3% +$9.78K
AUPH icon
1123
Aurinia Pharmaceuticals
AUPH
$1.91B
$396K 0.01%
30,564
+274
+0.9% +$3.49K
FFC
1124
Flaherty & Crumrine Preferred and Income Securities Fund
FFC
$777M
$395K 0.01%
17,387
MERC icon
1125
Mercer International
MERC
$42.3M
$393K 0.01%
30,804
-4,846
-14% -$71.8K

Similar funds

Oppenheimer & Co's Q2 2021 Portfolio in Review

As of Q2 2021, Oppenheimer & Co held 1,590 positions worth $5.58B, up 11% from $5.01B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Oppenheimer & Co deployed $189M of net new capital in Q2 2021, opening 158 new positions and adding to 732 existing holdings. Its largest new stake was Equity Commonwealth: 133,173 shares worth $3.49M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was State Street SPDR Bloomberg Convertible Securities ETF, an estimated $8.63M trimmed.

  • Oppenheimer & Co's largest Q2 2021 buy was Equity Commonwealth: 133,173 shares worth $3.49M.
  • Oppenheimer & Co added most to Amazon in Q2 2021, an estimated $10.8M increase.
  • Oppenheimer & Co's biggest Q2 2021 reduction was State Street SPDR Bloomberg Convertible Securities ETF, cutting an estimated $8.63M.
  • Oppenheimer & Co fully exited Armstrong World Industries in Q2 2021, selling an estimated $7.38M.
  • Oppenheimer & Co's ten largest holdings make up 18% of its $5.58B portfolio in Q2 2021.
  • Oppenheimer & Co opened 158 new positions and closed 88 in Q2 2021.
  • Oppenheimer & Co's portfolio value rose 11% quarter-over-quarter to $5.58B.

Based on Oppenheimer & Co's 13F filing for Q2 2021, filed 3 Aug 2021.